1. Home
  2. TLSA vs CKPT Comparison

TLSA vs CKPT Comparison

Compare TLSA & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TLSA
  • CKPT
  • Stock Information
  • Founded
  • TLSA 2013
  • CKPT 2014
  • Country
  • TLSA United Kingdom
  • CKPT United States
  • Employees
  • TLSA N/A
  • CKPT N/A
  • Industry
  • TLSA Biotechnology: Pharmaceutical Preparations
  • CKPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • TLSA Health Care
  • CKPT Health Care
  • Exchange
  • TLSA Nasdaq
  • CKPT Nasdaq
  • Market Cap
  • TLSA 87.8M
  • CKPT N/A
  • IPO Year
  • TLSA 2000
  • CKPT 2017
  • Fundamental
  • Price
  • TLSA $1.20
  • CKPT $3.77
  • Analyst Decision
  • TLSA
  • CKPT Strong Buy
  • Analyst Count
  • TLSA 0
  • CKPT 2
  • Target Price
  • TLSA N/A
  • CKPT $12.00
  • AVG Volume (30 Days)
  • TLSA 145.8K
  • CKPT 946.5K
  • Earning Date
  • TLSA 05-10-2024
  • CKPT 11-11-2024
  • Dividend Yield
  • TLSA N/A
  • CKPT N/A
  • EPS Growth
  • TLSA N/A
  • CKPT N/A
  • EPS
  • TLSA N/A
  • CKPT N/A
  • Revenue
  • TLSA N/A
  • CKPT $78,000.00
  • Revenue This Year
  • TLSA N/A
  • CKPT N/A
  • Revenue Next Year
  • TLSA N/A
  • CKPT $151,162.55
  • P/E Ratio
  • TLSA N/A
  • CKPT N/A
  • Revenue Growth
  • TLSA N/A
  • CKPT N/A
  • 52 Week Low
  • TLSA $0.41
  • CKPT $1.36
  • 52 Week High
  • TLSA $1.74
  • CKPT $3.95
  • Technical
  • Relative Strength Index (RSI)
  • TLSA 65.44
  • CKPT 84.67
  • Support Level
  • TLSA $0.83
  • CKPT $2.37
  • Resistance Level
  • TLSA $0.92
  • CKPT $2.54
  • Average True Range (ATR)
  • TLSA 0.09
  • CKPT 0.27
  • MACD
  • TLSA 0.03
  • CKPT 0.10
  • Stochastic Oscillator
  • TLSA 84.52
  • CKPT 88.60

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: